Abivax SA ((GB:0RA9)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Abivax S.A. is conducting a Phase 2b clinical study titled ‘A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn’s Disease.’ The study aims to assess the efficacy and safety of obefazimod as both induction and maintenance therapy for patients with moderately to severely active Crohn’s Disease who have not responded adequately to conventional or advanced therapies.
The study is testing an experimental drug, Obefazimod, administered in three different doses (50mg, 25mg, and 12.5mg) compared to a placebo. The purpose of this drug is to provide a new treatment option for individuals with Crohn’s Disease, potentially improving their quality of life.
This interventional study is randomized with a parallel assignment model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment.
The study began on May 16, 2024, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 27, 2025, indicating that the study is currently recruiting participants.
For investors, the progress of this study could significantly impact Abivax’s stock performance. Positive results could enhance investor confidence and position Abivax as a leader in Crohn’s Disease treatment, potentially affecting competitors in the pharmaceutical industry.
The study is ongoing, and further details can be found on the ClinicalTrials portal.